CN106018811A - Kit for detecting specificity of lip cancer - Google Patents
Kit for detecting specificity of lip cancer Download PDFInfo
- Publication number
- CN106018811A CN106018811A CN201610624046.XA CN201610624046A CN106018811A CN 106018811 A CN106018811 A CN 106018811A CN 201610624046 A CN201610624046 A CN 201610624046A CN 106018811 A CN106018811 A CN 106018811A
- Authority
- CN
- China
- Prior art keywords
- crisp1
- aptamer
- lip cancer
- dna
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4746—Cancer-associated SCM-recognition factor, CRISPP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kit for detecting specificity of lip cancer. An aptamer provided by the invention has good compatibility with human cysteinase-rich secretory proteins 1. By using the aptamer, the cysteinase-rich secretary proteins 1 in saliva can be captured, and the lip cancer is detected by virtue of the variation of the content of the cysteinase-rich secretary proteins 1. The cysteinase-rich secretary proteins 1 are prepared into a corresponding kit for screening the lip cancer. The kit has the advantages of high sensitivity and low cost.
Description
Technical field
The present invention relates to a kind of test kit for detecting lip cancer and detection method thereof.
Background technology
Lip cancer refers to that the malignant tumor betiding upper and lower lip is one of oral cavity common cancer, accounts in oral cancer
Vertical position, accounts for the 0.1%~0.5% of whole body malignant tumor, accounts for the 7.1%~15.0% of malignant tumor of mouth, American-European countries's lip cancer
Patient is more, accounts for the 20%~30% of oral cancer.Typically lower lip is easier than upper lip gets involved, and about 90%~95% occurs at vermilion border of lower lip
Portion, and be common at outer the 1/3 of W lower lip.Male patient is in the majority, and the ratio of men and women is 7:1.Age occurred frequently is 50~70 years old.Lip
The cancer overwhelming majority is the shape cell carcinoma of differentiated, how to occur on the basis of the optimum pathological changes taking biology, and its speed of growth is relatively slow,
Prognosis is preferable, and within general 5 years, survival rate is on 70%W, and the cause of disease of primary disease may be stimulated by foreign body for a long time with local, strong ultraviolet
Line irradiates relevant.Lip epithelium keratinization, white macula, skilful expense, granuloma and breach etc. are not healed for a long time, also may result in canceration.
Known in the art, saliva is that 10-40ng can be diagnosed as lip cancer rich in hemiamic acid secretory protein 1 concentration.Cause
This, the concentration of detection hemiamic acid secretory protein 1 becomes particularly important.
Aptamer (Aptamer, also known as aptamers, aptamer) is can high-affinity, certain life of combination of high specific
Thing leather El target strand widow's nucleic acid molecules (ssDNA or ssRNA).Aptamer is by index concentration Fas lignand system evolution technology
(Systematlc Evolutlon of Llgands by Exponentlal enrlchment, SELEX) is from synthetic
What in DNA/RNA library, screening obtained can combine the single stranded DNA/RNA of target molecules by high degree of specificity.Report aptamer
Target include metal ion, organic molecule, polypeptide, protein, cell even tissue etc..The molecular recognition merit of aptamer
Can be similar with antibody, there is the target identification ability the most higher with antibody molecule, but have the most excellent compared with antibody
Good characteristic, as molecular weight is little, can manufacture, not easy in inactivation, non-immunogenicity, be readily synthesized with labelling, quickly penetrate
Between tissue, good dynamic metabolism, different batches, product does not haves difference and has fine chemical stability, at biology
The fields such as detection, medical diagnosis on disease treatment have important application prospect.
Summary of the invention
It is an object of the invention to provide aptamer and the test kit thereof of a kind of specific bond CRISP1.
The aptamer that the present invention provides, is the single stranded DNA shown in sequence 1-15 of sequence table.
Described aptamer and CRISP1 albumen have preferable affinity.
Also described aptamer can be modified or transformed, obtain the derivant of described aptamer.
The derivant of described aptamer can be following any one:
A) described aptamer being deleted part or increases the nucleotide of partial complementarity, obtain has with described aptamer
There is the derivant of the aptamer of identical function;
B) described aptamer carrying out nucleotide replacement or part is modified, obtain has identical with described aptamer
The derivant of the aptamer of function;
C) transforming the skeleton of described aptamer as phosphorothioate backbone, obtain has phase with described aptamer
The derivant of the aptamer of congenerous;
D) aptamer transform peptide nucleic acid(PNA) as, obtain has the aptamer of identical function with described aptamer
Derivant;
E) after described aptamer being connected upper fluorescence, radioactivity and therapeutic substance, that obtain with described aptamer
There is the derivant of the aptamer of identical function.
Described aptamer can be used for the test kit of preparation detection CRISP1.
Utilize the aptamer of the present invention, in can capturing in saliva in CRISP1, thus for related oral cancer
Examination.Utilize the aptamer of the present invention, there is highly sensitive, low cost, the easy advantage prepared, easily preserve.The present invention has very
High using value.
Detailed description of the invention
Below example facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiment
Method, if no special instructions, is conventional method.
Embodiment 1, the acquisition of CRISP1 albumen
CRISP1 gene shown in Genbank:EAX04350 is carried out table by the eukaryotic expression mode that this area is conventional
Reach, it is thus achieved that corresponding desired polypeptides albumen.
The screening of embodiment 2 aptamer and preparation
Two ends comprise about 20 nucleotide, centre includes that the random nucleic acid library of 41 nucleotide is as follows in design:
5‘-TGGCACCTACGATCTAAGGCA(N41)GGACTACCAATGCAACGTCAC-3’;N41 represents 41 at random
Nucleotide.
Being double-stranded DNA by single-stranded DNA banks amplification, product is through 2% agarose gel electrophoresis and cuts glue recovery purification;To return
The double-stranded DNA received is template, and in vitro transcription goes out single stranded RNA random library, and transcription product is through PAGE purification.75 μ g RNA library warps
The anti-sieve of nitrocellulose filter removes the RNA molecule being combined with film, then with 2ugCRISP1 albumen, hatches 30min for 37 DEG C, reaction
Liquid filters through nitrocellulose filter, washs filter membrane;Then filter membrane is shredded, be placed in elution buffer (6mol/L carbamide,
0.55mol/L ammonium acetate, l.5mmol/LEDTA, 0.15%SDS) in boil 5min, centrifugal, take supernatant, dehydrated alcohol precipitates
RNA, and be redissolved in 20 μ 1DEPC water;With RNA for template RT-PCR amplifying doulbe-chain DNA, in vitro transcription goes out RNA library and uses
Screen in next round;Often in wheel screening process, RT-PCR obtains double-stranded DNA library, goes out with this double-stranded DNA for template in vitro transcription
RNA aptamer storehouse, screening carries out 12 altogether and takes turns.Having obtained 15 aptamers, its sequence is respectively shown in SEQ ID NO:1-15.Tool
Body sequence is as follows:
CRISP1-1:
TGGCACCTACGATCTAAGGCAATCCCATATATGTTCCACACACTCGCAACTTATCCGCTACA
GGACTACCAATGCAACGTCAC
CRISP1-2:
TGGCACCTACGATCTAAGGCATTCCGCCATAAATAAGATTCACATCACGACATCGATCACAC
GGACTACCAATGCAACGTCAC
CRISP1-3:
TGGCACCTACGATCTAAGGCACTTAATCAACATATCTCTTCTGTATTCTCTCCACGCATACA
GGACTACCAATGCAACGTCAC
CRISP1-4:
TGGCACCTACGATCTAAGGCAACGTCTCCAATCCGCACTTATAATTATGTTCTTACCTAAGA
GGACTACCAATGCAACGTCAC
CRISP1-5:
TGGCACCTACGATCTAAGGCACGCTCATCACCATCTCCTACCTATATACATCACCTTCGCCT
GGACTACCAATGCAACGTCAC
CRISP1-6:
TGGCACCTACGATCTAAGGCACATATCATCCTCCATACACGACCAACCACTCCGTCTTCACT
GGACTACCAATGCAACGTCAC
CRISP1-7:
TGGCACCTACGATCTAAGGCAAACAAACACTCTCGCACATTACCTTATTTATCAAGAATATA
GGACTACCAATGCAACGTCAC
CRISP1-8:
TGGCACCTACGATCTAAGGCACCGCTTATCTACACTAAATACAATTTCCTCCTCACCCTCCA
GGACTACCAATGCAACGTCAC
CRISP1-9:
TGGCACCTACGATCTAAGGCACACGCCTCCAATATCAACTTAATAATACACCACTAATTTCT
GGACTACCAATGCAACGTCAC
CRISP1-10:
TGGCACCTACGATCTAAGGCACACACGCCACTTATACAACAATCCAACCGCCTACCACTACT
GGACTACCAATGCAACGTCAC
CRISP1-11:
TGGCACCTACGATCTAAGGCATAGCATCACTACTCGCTATTTCCTATAATCCTAGCCTTATA
GGACTACCAATGCAACGTCAC
CRISP1-12:
TGGCACCTACGATCTAAGGCACTAGAAACTCCAACACATACACACACAGACCCGCTCCATAA
GGACTACCAATGCAACGTCAC
CRISP1-13:
TGGCACCTACGATCTAAGGCATCGCATAACGCTCCACAATATTAACATACTTCTCTTCTTAT
GGACTACCAATGCAACGTCAC
CRISP1-14:
TGGCACCTACGATCTAAGGCATCATAATATTCGCTCACTCTAATCATACATTATCTTCTTGT
GGACTACCAATGCAACGTCAC
CRISP1-15:
TGGCACCTACGATCTAAGGCAATAATATTCGCTCACTATAATCAACATTATCTTCTTGTTCT
GGACTACCAATGCAACGTCAC
The performance measurement of embodiment 3 protein binding aptamer
Aptamer taking 2.0 μ g respectively, digests lh with calf intestinal alkaline phosphatase (CIP) 37 DEG C, purification reclaims and removes phosphoric acid
The RNA changed;By T4 polynucleotide kinase labelling [γ-32P] ATP in dephosphorylized RNA molecule end.10nmol radioactivity
The aptamer of labelling with variable concentrations (1-200nM) CRISP137 DEG C respectively hatches 30min, and each group reactant liquor is through cellulose nitrate
Element membrane filtration mistake, washs filter membrane, is dried filter membrane, and liquid scintillation counter measures the exit dose of residual on filter membrane, and same sample is parallel does two
Secondary mensuration.Calculate the dissociation constant of each aptamer and destination protein.Result is as follows:
Title | Dissociation constant Kd (unit nM) |
CRISP1-1 | 9.9 |
CRISP1-2 | 9.7 |
CRISP1-3 | 9.8 |
CRISP1-4 | 9.6 |
CRISP1-5 | 9.4 |
CRISP1-6 | 9.3 |
CRISP1-7 | 9.4 |
CRISP1-8 | 9.6 |
CRISP1-9 | 9.0 |
CRISP1-10 | 9.7 |
CRISP1-11 | 9.6 |
CRISP1-12 | 9.7 |
CRISP1-13 | 9.0 |
CRISP1-14 | 8.9 |
CRISP1-15 | 8.8 |
PBS blank | Without binding ability |
Aptamer specificity analyses and stability analysis described in embodiment 4
It is respectively adopted human albumin, immune globulin, vibrio cholera VgrG3C albumen, escherichia coli outer membrane protein
A, COCH albumen, CRISP1 albumen, carry out specific detection with 15 aptamers, find through binding tests, these aptamers
Do not combine with these albumen, and only keep higher specificity with CRISP1 protein binding.
By described aptamer, take 0.2ug, be respectively placed in the serum of room temperature, aqueous solution, place two weeks.Pass through RT-
PCR detects, and finds its Stability Analysis of Structures of placement of three weeks, is not degraded.
The diagnosis of aptamer disease described in embodiment 5
Take the salivation thing of 9 lip cancer patients and 3 normal persons, use normal saline dilution, it is thus achieved that target sample.
By 15 markd aptamers of coupling respectively with the secretions mixing 30min of 9 patients and 3 normal persons,
Separated by biotin, the content of quantitative analysis CRISP1 therein albumen, found by analysis, in 9 oral cancer patients
The content of CRISP1 albumen dramatically increases, and has exceeded the threshold value of regulation.Reach the diagnostic criteria of lip cancer.As can be seen here, it is examined
Disconnected effect is preferable.
These are only the preferred embodiments of the present invention, be not limited to the present invention, for those skilled in the art
For Yuan, all any modification, equivalent substitution and improvement etc. done within the spirit and principles in the present invention, should be included in this
Within the protection domain of invention.
Sequence table
< 110 > Chen Bo
The test kit of < 120 > mono-species-specific diagnosis lip cancer
〈160〉15
〈210〉1
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-1
TGGCACCTACGATCTAAGGCAATCCCATATATGTTCCACACACTCGCAACTTATCCGCTACAGGACTACCAATGCAACGTCAC
〈210〉2
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-2
TGGCACCTACGATCTAAGGCATTCCGCCATAAATAAGATTCACATCACGACATCGATCACACGGACTACCAATGCAACGTCAC
〈210〉3
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-3
TGGCACCTACGATCTAAGGCACTTAATCAACATATCTCTTCTGTATTCTCTCCACGCATACAGGACTACCAATGCAACGTCAC
〈210〉4
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-4
TGGCACCTACGATCTAAGGCAACGTCTCCAATCCGCACTTATAATTATGTTCTTACCTAAGAGGACTACCAATGCAACGTCAC
〈210〉5
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-5
TGGCACCTACGATCTAAGGCACGCTCATCACCATCTCCTACCTATATACATCACCTTCGCCTGGACTACCAATGCAACGTCAC
〈210〉6
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-6
TGGCACCTACGATCTAAGGCACATATCATCCTCCATACACGACCAACCACTCCGTCTTCACTGGACTACCAATGCAACGTCAC
〈210〉7
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-7
TGGCACCTACGATCTAAGGCAAACAAACACTCTCGCACATTACCTTATTTATCAAGAATATAGGACTACCAATGCAACGTCAC
〈210〉8
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-8
TGGCACCTACGATCTAAGGCACCGCTTATCTACACTAAATACAATTTCCTCCTCACCCTCCAGGACTACCAATGCAACGTCAC
〈210〉9
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-9
TGGCACCTACGATCTAAGGCACACGCCTCCAATATCAACTTAATAATACACCACTAATTTCTGGACTACCAATGCAACGTCAC
〈210〉10
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-10
TGGCACCTACGATCTAAGGCACACACGCCACTTATACAACAATCCAACCGCCTACCACTACTGGACTACCAATGCAACGTCAC
〈210〉11
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-11
TGGCACCTACGATCTAAGGCATAGCATCACTACTCGCTATTTCCTATAATCCTAGCCTTATAGGACTACCAATGCAACGTCAC
〈210〉12
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-12
TGGCACCTACGATCTAAGGCACTAGAAACTCCAACACATACACACACAGACCCGCTCCATAAGGACTACCAATGCAACGTCAC
〈210〉13
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-13
TGGCACCTACGATCTAAGGCATCGCATAACGCTCCACAATATTAACATACTTCTCTTCTTATGGACTACCAATGCAACGTCAC
〈210〉14
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-14
TGGCACCTACGATCTAAGGCATCATAATATTCGCTCACTCTAATCATACATTATCTTCTTGTGGACTACCAATGCAACGTCAC
〈210〉15
〈211〉 83
〈212〉DNA
< 213 > artificial sequence
〈400〉CRISP1-15
TGGCACCTACGATCTAAGGCAATAATATTCGCTCACTATAATCAACATTATCTTCTTGTTCTGGACTACCAATGCAACGTCAC
Claims (3)
1. for a test kit for lip cancer detection, its contain can the nucleic acid that is combined with CRISP1 protein-specific of specificity suitable
Body.
2. test kit as claimed in claim 1, it is characterised in that: the sequence of described aptamer such as SEQ ID No:10 institute
State.
3. the method detecting lip cancer, it is characterised in that utilize the test kit described in any one of claim 1-2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610624046.XA CN106018811A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510775706.XA CN105353126B (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610624046.XA CN106018811A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510775706.XA Division CN105353126B (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106018811A true CN106018811A (en) | 2016-10-12 |
Family
ID=55329130
Family Applications (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610623978.2A Pending CN106053844A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624169.3A Withdrawn CN106226533A (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610623940.5A Pending CN106053842A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624011.6A Pending CN106018810A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201610624264.3A Pending CN106018813A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201610624182.9A Pending CN106053846A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624160.2A Withdrawn CN106226532A (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610623980.XA Pending CN106018833A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201610624012.0A Pending CN106053845A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624284.0A Pending CN106053847A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624046.XA Pending CN106018811A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201510775706.XA Expired - Fee Related CN105353126B (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610623977.8A Pending CN106053843A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624258.8A Pending CN106018812A (en) | 2015-11-15 | 2015-11-15 | Kit for specific detection of lip cancer |
CN201610624332.6A Withdrawn CN106226534A (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
Family Applications Before (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610623978.2A Pending CN106053844A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624169.3A Withdrawn CN106226533A (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610623940.5A Pending CN106053842A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624011.6A Pending CN106018810A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201610624264.3A Pending CN106018813A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201610624182.9A Pending CN106053846A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624160.2A Withdrawn CN106226532A (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610623980.XA Pending CN106018833A (en) | 2015-11-15 | 2015-11-15 | Kit for detecting specificity of lip cancer |
CN201610624012.0A Pending CN106053845A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624284.0A Pending CN106053847A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510775706.XA Expired - Fee Related CN105353126B (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
CN201610623977.8A Pending CN106053843A (en) | 2015-11-15 | 2015-11-15 | Lip cancer specificity detection kit |
CN201610624258.8A Pending CN106018812A (en) | 2015-11-15 | 2015-11-15 | Kit for specific detection of lip cancer |
CN201610624332.6A Withdrawn CN106226534A (en) | 2015-11-15 | 2015-11-15 | A kind of test kit of lip cancer specific detection |
Country Status (1)
Country | Link |
---|---|
CN (15) | CN106053844A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103308691A (en) * | 2013-05-22 | 2013-09-18 | 苏州市马尔泰新材料有限公司 | Application of secretory protein 1 rich in cysteine in preparation of product for diagnosing cheilocarcinoma |
CN104818278A (en) * | 2015-04-17 | 2015-08-05 | 刘红卫 | Aptamer capable of being in specific binding to TS/MDEP protein in gastric cancer cells |
CN104830867A (en) * | 2015-06-07 | 2015-08-12 | 杨洋 | Aptamer capable of being specifically combined with DKK1 protein in cancer cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2375254A1 (en) * | 2006-02-17 | 2011-10-12 | The Children's Medical Center Corporation | Free NGAL as a biomarker for cancer |
EP2674756B1 (en) * | 2009-09-10 | 2016-08-03 | Bruker Daltonik GmbH | Determining the expression status of human epidermal growth factor receptor 2 (HER2) in biological samples |
WO2012075069A2 (en) * | 2010-12-02 | 2012-06-07 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with cancer and methods of use thereof |
CN103267863A (en) * | 2013-05-22 | 2013-08-28 | 苏州市马尔泰新材料有限公司 | CRISP1 (cystein-rich secretory protein 1) test paper for quickly diagnosing carcinoma of maxillary sinus |
CN103278645B (en) * | 2013-05-22 | 2015-01-28 | 上海市第十人民医院 | Application of gold-labelled test strip for quickly diagnosing carcinoma of lip |
CN103308682A (en) * | 2013-05-22 | 2013-09-18 | 苏州市马尔泰新材料有限公司 | Kit for rapid lip cancer diagnosis |
-
2015
- 2015-11-15 CN CN201610623978.2A patent/CN106053844A/en active Pending
- 2015-11-15 CN CN201610624169.3A patent/CN106226533A/en not_active Withdrawn
- 2015-11-15 CN CN201610623940.5A patent/CN106053842A/en active Pending
- 2015-11-15 CN CN201610624011.6A patent/CN106018810A/en active Pending
- 2015-11-15 CN CN201610624264.3A patent/CN106018813A/en active Pending
- 2015-11-15 CN CN201610624182.9A patent/CN106053846A/en active Pending
- 2015-11-15 CN CN201610624160.2A patent/CN106226532A/en not_active Withdrawn
- 2015-11-15 CN CN201610623980.XA patent/CN106018833A/en active Pending
- 2015-11-15 CN CN201610624012.0A patent/CN106053845A/en active Pending
- 2015-11-15 CN CN201610624284.0A patent/CN106053847A/en active Pending
- 2015-11-15 CN CN201610624046.XA patent/CN106018811A/en active Pending
- 2015-11-15 CN CN201510775706.XA patent/CN105353126B/en not_active Expired - Fee Related
- 2015-11-15 CN CN201610623977.8A patent/CN106053843A/en active Pending
- 2015-11-15 CN CN201610624258.8A patent/CN106018812A/en active Pending
- 2015-11-15 CN CN201610624332.6A patent/CN106226534A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103308691A (en) * | 2013-05-22 | 2013-09-18 | 苏州市马尔泰新材料有限公司 | Application of secretory protein 1 rich in cysteine in preparation of product for diagnosing cheilocarcinoma |
CN104818278A (en) * | 2015-04-17 | 2015-08-05 | 刘红卫 | Aptamer capable of being in specific binding to TS/MDEP protein in gastric cancer cells |
CN104830867A (en) * | 2015-06-07 | 2015-08-12 | 杨洋 | Aptamer capable of being specifically combined with DKK1 protein in cancer cells |
Also Published As
Publication number | Publication date |
---|---|
CN106053845A (en) | 2016-10-26 |
CN106226532A (en) | 2016-12-14 |
CN106053846A (en) | 2016-10-26 |
CN105353126A (en) | 2016-02-24 |
CN106053842A (en) | 2016-10-26 |
CN106226534A (en) | 2016-12-14 |
CN106018812A (en) | 2016-10-12 |
CN106053844A (en) | 2016-10-26 |
CN105353126B (en) | 2016-11-02 |
CN106018833A (en) | 2016-10-12 |
CN106053843A (en) | 2016-10-26 |
CN106053847A (en) | 2016-10-26 |
CN106226533A (en) | 2016-12-14 |
CN106018810A (en) | 2016-10-12 |
CN106018813A (en) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105203763B (en) | A kind of test kit of oral cancer specific detection | |
CN105353126B (en) | A kind of test kit of lip cancer specific detection | |
CN105842444A (en) | Kit for specific detection on endometrial cancer | |
CN105334328B (en) | Kit and method for detecting ophthalmic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161012 |
|
WD01 | Invention patent application deemed withdrawn after publication |